🔴 Intellia Therapeutics is trading 5.7% down today on dilution concerns and heavy insider selling

Intellia Therapeutics is trading 5.7% down at $13.49 today as investors react to a $180 million equity offering and a heavy insider-selling profile.

• The stock remains under pressure following an April equity offering priced at $10.75 per share, which has raised significant dilution and governance concerns among shareholders.
• Downside volatility is being amplified by an elevated short interest of 45.4% of the float and broader profit-taking across the biotechnology sector following a prior rally.